rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, no evidence of association was observed between prognosis in osteosarcoma and <i>ERCC1</i> rs11615, <i>ERCC1</i> rs3212986, <i>ERCC1</i> rs2298881, <i>ERCC2</i> rs13181, <i>ERCC4</i> rs1800067, and <i>ERCC5</i> rs1047768 polymorphisms.
|
29950854 |
2018 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.
|
28977987 |
2017 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Haplotype containing the rs1799793-T and rs11615-T alleles was associated with a statistically increased osteosarcoma risk, OR (95% CI) = 1.47 (1.12-1.92).
|
28474168 |
2017 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.
|
26345951 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our findings suggest that ERCC1 rs11615 and ERCC1 rs2298881 genetic polymorphisms are significantly associated with poor response to chemotherapy and unfavourable survival of osteosarcoma.
|
26339355 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the Cox proportional hazards model, after adjusting for potential confounding factors, we found that individuals carrying CC genotype of ERCC1 rs11615 was associated with decreased risk of death from osteosarcoma, and the HR (95% CI) was 0.43 (0.15-0.93).
|
25755792 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results suggest that the ERCC1 rs11615 polymorphism might influence the response to cisplatin-based chemotherapy and affect the clinical outcome for osteosarcoma patients.
|
26400354 |
2015 |
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Excision repair cross-complementing (ERCC) group 2 (XPD; rs13181 and rs1799793), group 5 (XPG; rs17655) and group 1 (XPA; rs3212986 and rs11615) polymorphisms were analyzed in a group of 130 homogenously treated patients with high-grade osteosarcoma, for association with event-free survival (EFS), using the Kaplan-Meier plots and log-rank test.
|
21826087 |
2012 |